Latest News

View allAccessAL amyloidosisCAR-TConferencesMPEMyelomaNewsPatient evidenceVideos

Living with myeloma finding my way to greater well-being

Every myeloma patient has a story to tell. And every story captures a very personal experience of our incurable blood cancer. Living with myeloma is more than navigating the physical challenges of illness and treatment. It is also about finding a path through mental health issues: toxic thoughts, rollercoaster emotions and imperilled well-being. Because myeloma…

Read more

The National Institute for Health and Care Excellence (NICE) approves the use of elranatamab as a fourth-line treatment for myeloma in England and Wales

  On the 21st of June NICE, the United Kingdom’s public body for medicine appraisals, approved the use of the UK’s first bispecific drug for myeloma, elranatamab. Evidence from an ongoing clinical trial showed that the drug can increase the length of time people are in remission. Based on this evidence, elranatamab, commercially known as…

Read more

European Commission approves CAR T-cell therapy ciltacabtagene autoleucel in earlier lines of therapy for relapsed and refractory myeloma

The European Commission has approved marketing authorisation extension for the CAR-T treatment ciltacabtagene autoleucel (Carvytki®), also known as cilta-cel, for use in patients who have received at least one prior therapy, including an immunomodulatory agent (IMiD – such as lenalidomide and pomalidomide) and a proteasome inhibitor (PI – such as bortezomib or carfilzomib), have demonstrated disease progression…

Read more

MPE launches the Myeloma and AL Amyloidosis European Clinical Trial Navigator

Brussels, 23 April 2024 – Myeloma Patients Europe (MPE) has launched today the English version of the Myeloma and AL Amyloidosis European Clinical Trial Navigator, an online search tool to learn about and find clinical trials for myeloma, monoclonal gammopathy of undetermined significance (MGUS), smouldering multiple myeloma (SMM) and AL amyloidosis in Europe. With this tool, MPE wants to facilitate the search…

Read more

European Commission grants final approval for CAR-T treatment idecabtagene vicleucel (Abecma) in earlier lines of therapy for relapsed and refractory myeloma

The European Commission has granted the final approval for the extension of the marketing authorisation for idecabtagene vicleucel (ide-cel), a CAR-T treatment marketed by Bristol-Myers Squibb (BMS) as Abecma®. Ide-cel has previously been approved for the treatment of patients with relapsed and refractory myeloma, who have received at least three previous lines of therapy. The…

Read more
April

May 2026

June
MO
TU
WE
TH
FR
SA
SU
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
Events for 1st May
No Events
Events for 2nd May
No Events
Events for 3rd May
No Events
Events for 4th May
No Events
Events for 5th May
No Events
Events for 6th May
No Events
Events for 7th May
No Events
Events for 8th May
No Events
Events for 9th May
No Events
Events for 10th May
No Events
Events for 11th May
No Events
Events for 12th May
No Events
Events for 13th May
No Events
Events for 14th May
No Events
Events for 15th May
No Events
Events for 16th May
No Events
Events for 17th May
No Events
Events for 18th May
No Events
Events for 19th May
No Events
Events for 20th May
No Events
Events for 21st May
No Events
Events for 22nd May
No Events
Events for 23rd May
No Events
Events for 24th May
No Events
Events for 25th May
No Events
Events for 26th May
No Events
Events for 27th May
No Events
Events for 28th May
No Events
Events for 29th May
No Events
Events for 30th May
No Events
Events for 31st May
No Events